CD117 expression on blast cells in acute myeloid leukemia.
DOI:
https://doi.org/10.26641/2307-0404.2015.3.53688Keywords:
acute myeloid leukemia, blast cells, immunophenotyping, target therapy, CD117Abstract
The aim of the present work was to analyze the frequency of CD117 (c-KIT) antigen expression on the blast cells in acute myeloid leukemia (AML), evaluation of the presence of the relationship between the expression of the c-KIT and leukemia according to the FAB classification and definition of co-expression of the antigen CD117, antigens CD33 and CD34. The data of 47 patients with AML were diagnosed. M0 AML variant was established in 3 (6%) patients, M1 – in 2 (4%), M2 – in 9 (20%), M4 – in 22 (47%) and M5 – in 11 (23%). For immunophenotypic studies monoclonal antibodies (mAb) that detect antigens of anti-CD34, anti-CD33 and anti-CD117 (Becton Dickinson, USA) were used. The presence of the antigen CD117 was detected in 39 people, accounting for 83% of all surveyed. Antigen c-KIT was present in 48.1±17.0% cells on average: in all 3 cases – AML M0, in2 cases of AML M1, in 6 cases – AML M2, 20 of 22 cases – AML M4 and in 8 of 11 AML M5 cases. Average levels of CD117 in investigated leukemia cases statistically differed significantly (p=0.0067). Among 39 CD117- positive patients in 25 (53%) co-expression of CD117+/CD34+ was revealed. Expression of CD117+/CD34- was observed in 14 cases (30%), CD117-/CD34+ – in 4 cases (8,5%), CD117-/CD34- – in 4 cases (8.5%). CD34 had of 64% of cells of myeloid origin. A high positive correlation between expression of CD117 and CD34 (r=+0,5169) was determined, being statistically significant (p<0.0067). CD33 antigen was present on 81% of the studied cells. A weak negative correlation between expression of CD117 and CD33 (r=-0,2247), was revealed, being statistically significant (p>0,0067).
References
Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia AML or not amenable to conventional therapy for the disea-se. Blood, 2005;105(3):986-93. 2. Wandzioch E, Edling C, Pulmer R, et al. Acti-vation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood. 2004;104:51-7. 3. Advani AS. C-kit as a target in the treatment of acu¬te myelogenous leukemia. Curr. Hematol. Rep. 2005;4(1):51-8. 4. Paschka P, Marcucci G, Ruppert AS, et al. Adver-se pro¬g¬nostic significance of KIT mutations in adult acute mye¬loid leukemia with inv(16) and t(8;21): a Cancer and Leu¬ke¬mia Group B Study. J. Clin. Oncol. 2006;24(24):3904–11. 5. Tsao AS, Kantarjian H, Thomas D et al. C-kit re-ceptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004;28:373-8. 6. Lennartsson J, Voytyuk O, Heiss E, et al. C-Kit signal transduction and involvement in cancer. Cancer Ther. 2005;3:5–28. 7. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006;354(24):2531-41. 8. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute mye¬loblastic leukemia cells. Blood. 2011;178(11):2962–8. 9. Hasskarl J. Sorafenib. Recent. Results. Cancer Res. 2010;184:61-70. 10. Piccaluga PP, Malagola M, Rondoni M, et al. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leuke-mia. Results of an Italian Multicentric Phase II Study. Haematologica. 2007;92(12):1721-2. 11. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 2008;50:1198-1206. 12. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920-5. 13. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuke¬mia Res, 2001;25:572-6. 14. Kuriu A, Ikeda H, Kanakura Y, et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-on-cogene c-kit product. Blood. 2011;178(11):2834–40. 15. Bennett JM, Catovsky D, Daniel MT, et al. Pro-posals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Hae¬matol. 1976; 33(4):451–8. 16. Heidel F, Cortes J, Rucker FG, et al. Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib. Cancer. 2007;109:907-14. 17. Roskoski R. Structure and regulation of Kit pro-tein-tyrosine kinase - the stem cell factor receptor. Bio-chem. Biophys. Res. Commun. 2005;338:1307-15. 18. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 1996;10:877-95. 19. Liu H, Chen X, Focia P, He X. Structural basis for stem cell factor–KIT signaling and activation of class III receptor tyrosine kinases. EMBO J. 2007;26:891-901. 20. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhi-bitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003;102:795-801. 21. Kindler T, Breitenbuecher F, Marx A, et al. The ef¬ficacy and safety of imatinib in adult patients with c-kit po¬sitive acute myeloid leukemia. Blood. 2004;103:3644-54. 22. Zaker F, Mohammadzadeh M, Moham¬madi M. Detection of KIT and FLT3 Mutations in Acute Mye-loid Leukemia with Different Subtypes. Arch Iran Med. 2010;13:21–5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
